U.S. stock night trading volatility: Clinical trial failure severely impacts stock price, Mereo Biopharma falls 7.94% in after-hours trading, raising market concerns

U.S. Stock Night Market Movements Mereo Biopharma fell 7.94% in the night market. Based on recent news, On December 29, Mereo BioPharma announced that its two Phase III clinical trials failed to meet primary endpoints and did not significantly reduce the fracture rate in patients with osteogenesis imperfecta. This news led to a significant drop in the company's stock price of over 90%. On December 29, Mereo BioPharma stated that it is conducting further analysis to explore additional data and is engaged in cost management and collaboration discussions. Although there was an improvement in bone density, the failure to meet primary endpoints had a negative impact on the stock price. On December 30, analysts adjusted the target price for Mereo BioPharma's stock. While they remain optimistic about its long-term potential, confidence in the stock price has decreased in the short term. The biopharmaceutical industry has been highly volatile recently, and investors should exercise caution. Stocks with High Trading Volume in the Industry Vanda Pharmaceuticals rose 21.19% in the night market. Based on recent key news: On December 30, Vanda Pharmaceuticals announced that its drug NEREUS™ received approval from the U.S. Food and Drug Administration for the prevention of motion-induced vomiting. This approval marks a historic scientific milestone in the prevention of motion sickness, driving the stock price up. On December 30, Vanda Pharmaceuticals' NEREUS™ became the first drug approved for the treatment of motion-induced vomiting in over 40 years. The drug works by blocking brain receptors associated with nausea and vomiting, significantly reducing vomiting, which led to a substantial increase in the stock price. On December 30, Vanda Pharmaceuticals closed at $7.03 in regular trading on Nasdaq, with the stock price soaring to $8.50 in night trading, an increase of 20.91%. This price movement reflects the market's positive response to the FDA approval. The pharmaceutical industry's innovative drug approvals have received a positive market reaction. BeiGene fell 1.48% in the night market. Based on recent news: On December 29, the decline in BeiGene's stock price may be related to market concerns about the pricing policies for innovative drugs. The Pharmaceutical Promotion Association suggested supporting the development of the innovative drug industry through tax deductions for commercial health insurance, but this was not adopted, leading to increased market doubts about policy support. On December 28, ongoing discussions within the industry regarding drug procurement policies may affect investor confidence. The opinions of policymakers have not been widely adopted, increasing market uncertainty about the policies and causing stock price fluctuations. On December 27, market optimism regarding the future development of China's pharmaceutical industry has weakened. Although the industry's rise is related to institutional optimization, the uncertainty of policy implementation in the short term still affects stock price performance. Changes in pharmaceutical industry policies impact stock price volatility. Recursion Pharmaceuticals rose 0.49% in the night market. Based on recent key news: On December 30th, Recursion Pharmaceuticals experienced a volume-reduced rebound during the trading session, with short-term funds testing the upward pull, leading to a slight increase in sentiment within the pharmaceutical innovation sector. Technical indicators show effective bottom support, and indicators like MACD have initially strengthened, driving the stock price up. Source: Zhitong Finance On December 30th, Recursion Pharmaceuticals was caught in a low-level tug-of-war, repeatedly contesting the USD 1.7-2.2 range. The pharmaceutical sector as a whole remained quiet, with funds' positions compressed, and signs of community main forces lurking began to emerge, resulting in increased stock price volatility. Source: Wall Street Insight On December 29th, Recursion Pharmaceuticals executive Najat Khan sold company shares for a transaction amount of USD 548,592, which may impact market sentiment. Source: SEC announcement. The capital flow in the pharmaceutical sector is unstable, and risks need to be monitored